The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.
Published: July 10, 2017 at 02:00AM
from NYT Health https://ift.tt/2u07daw
The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.
Published: July 10, 2017 at 02:00AM
from NYT Health https://ift.tt/2u07daw
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)